Advanced level According to the ATS/IDSA Guidelines for CAP, empiric… — Medical Notes Dr. Ayman Radwan — TG.ME

Advanced level According to the ATS/IDSA Guidelines for CAP, empiric regimens must cover Streptococcus pneumoniae, Haemophilus influenzae, and atypical pathogens (Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella pneumophila). While Cefazolin has lower minimum inhibitory concentrations (MICs) against S. pneumoniae than 3rd-generation agents, they have poor outer-membrane penetration and low beta-lactamase stability against Gram-negative respiratory pathogens like H. influenzae and Moraxella catarrhalis. Ceftriaxone provides the necessary Gram-negative coverage, and the added macrolide (or fluoroquinolone) bridges the atypical gap. ................... (3) h-MRSA: most isolate is MSSA but a minor subpopulation is resistant usually slow growing can easily be missed and reported as MSSA here the sensitivity report mismatches the clinical outcome it should considered as MRSA mechanism : The classic majority of cells are under stringent, un-induced transcriptional repression by the upstream MecI repressor. Concurrently, phenotypic divergence is heavily dictated by mutations in chromosomal auxiliary genes (such as the femA/B or mur pathways). Because they encode the enzymes that construct the essential glycine interpeptide cross-bridges of the staphylococcal cell wall, any alteration means PBP2a cannot function efficiently for further details read this paper doi: 10.1371/journal.pone.0082814 the gold standard test here is Population Analysis Profile (PAP-AUC) ........................ (4) MRSA MRSA is driven by the acquisition of the mecA gene (via the SCCmec element), which encodes PBP2a blocking the site of action of penicillin and cephalosporin ............ Anti MRSA are : -vancomycin -linezolid -daptomycin -fifth generation cephalosporins (Ceftaroline) NB: Cefepime (4th gen) has zero anti-MRSA activity -clindamycin can be used as anti MRSA with suscess rate 60-80% typically for minor skin infection NB: If an isolate is erythromycin-resistant but clindamycin-susceptible, a D-zone test must be performed to check for inducible clindamycin resistance (erm gene activation). If positive, clindamycin will fail clinically .................. high yield clinical tip ,suggested approach for early identification and de escalation for lazy internists and antibiotic eager surgeon أسامة رضوان this will easily solve a nightmare for ENT doctors (where emrical anti MRSA +anti psuedomonal are needed ) when you start emprical vancomycin , the ideal plan to de escalate as limited resources protocol where rapid molecular arrays are unavailable, follow this strict diagnostic cascade: (1)For Pneumonia: Check the nasal MRSA swab; if negative, immediately stop Vancomycin. (2) For Deep Collections & Endovascular Targets (Osteomyelitis, Malignant Otitis Externa, Deep Abscesses, Endocarditis): Do not rely on nasal swabs. Rely strictly on early microscopic morphology: (a)If the morphology reveals bacilli= Discontinue Vancomycin immediately. There is zero role for anti-Gram-positive coverage here. For ENT nightmares like malignant otitis externa, this allows the team to aggressively maximize anti-pseudomonal coverage (dual therapy by adding Ciprofloxacin) without cluttering the regimen with redundant glycopeptides. (b) If the morphology confirms cocci = Maintain empiric Vancomycin coverage unconditionally. Do not attempt to de-escalate based on intermediate species identification tests (such as coagulase assays), as hospital-acquired coagulase-negative staphylococci carry high rates of methicillin resistance. ............................. Real-World Diagnostic FAQ Can we rely on the Cefoxitin (30 mcg) disk diffusion assay as a standard routine diagnostic test to confirm or exclude MRSA? Mechanistically yes, but chronologically no. ⬇️⬇️KEEP READING⬇️⬇️